Accepted for Publication: July 27, 2022.
Published Online: September 19, 2022. doi:10.1001/jamainternmed.2022.4138
Corresponding Author: Aaron S. Kesselheim, MD, JD, MPH, Program On Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, 1620 Tremont St, Ste 3030, Boston, MA 02120 (email@example.com).
Author Contributions: Mr Daval had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Daval, Kesselheim.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Daval, Avorn.
Critical revision of the manuscript for important intellectual content: All authors.
Obtained funding: Kesselheim.
Administrative, technical, or material support: Avorn.
Supervision: Avorn, Kesselheim.
Conflict of Interest Disclosures: Dr Kesselheim reported personal fees from the state of West Virginia for having served as an expert witness in a case against various opioid manufacturers (2021-2022) outside the submitted work. No other disclosures were reported.
Funding/Support: This work was supported by grants from Arnold Ventures.
Role of the Funder/Sponsor: The funders had no role in the preparation, review, or approval of the manuscript or the decision to submit the manuscript for publication.
S , Somerville
H , DeRosa
A . Elizabeth Holmes: what happens next to Theranos founder found guilty of fraud. The Wall Street Journal. January 13, 2022.
United States v Park, 421 US 658 (1975).
P . Credible deterrence: FDA and the Park Doctrine in the 21st century. Food Drug Law J
. 2013;68(2):137-188, i.PubMedGoogle Scholar
US Government Accountability Office. Food and Drug Administration: improved monitoring and development of performance measures needed to strengthen oversight of criminal and misconduct investigations. January 29, 2010. Accessed August 8, 2022. https://www.gao.gov/products/gao-10-221
MA . Do we need stronger sanctions to ensure legal compliance by pharmaceutical firms? Food Drug Law J
. 2015;70(3):435-452, ii.PubMedGoogle Scholar
KB, . The crime of being in charge: executive culpability and collateral consequences. Am Crim Law Rev
. 2014;51(4):799-836.Google Scholar
United States v Dotterweich, 320 US 277 (1943).
Bohner v Burwell, 2016 WL 8716339 (ED Pa 2016).
United States v Huggins, 2011 WL 6180623 (ED Pa 2011).
United States v Higgins, 2011 WL 6088576 (ED Pa 2011).
United States v Facteau, 2020 WL 5517573 (2020).
United States v Baxter, 2020 WL 5984560 (WD Va 2020).
United States v Purdue Frederick Co Inc, 495 F Supp 2d 569 (WD Va 2007).
Friedman v Sebelius, 686 F3d 813 (DC Cir 2012).
United States v Brown’s Compounding Center, Inc, 2017 WL 10242260 (D Colo 2017).